Sutureless Lyophilized Amniotic Membrane Grafting for Corneal Epithelial Defects.
Journal
Eye & contact lens
ISSN: 1542-233X
Titre abrégé: Eye Contact Lens
Pays: United States
ID NLM: 101160941
Informations de publication
Date de publication:
01 Oct 2022
01 Oct 2022
Historique:
accepted:
02
05
2022
entrez:
26
9
2022
pubmed:
27
9
2022
medline:
28
9
2022
Statut:
ppublish
Résumé
To report the tolerability, safety, and efficacy of the lyophilized amniotic membrane (AM) Visio-AMTRIX placed under a bandage contact lens (BCL) in treating persistent epithelial defects (PEDs). This retrospective study included consecutive patients with PEDs treated with a lyophilized AM placed under the BCL. Patients with PEDs who did not respond to medical treatment were included. Patients with a follow-up time less than 3 months were excluded. Eleven eyes of 11 patients (mean age, 61.6±15.9 years) were included. Time from PED presentation to AM transplantation (AMT) was 27.7±4.9 days, with the mean PED area of 13.2±11.3 mm2. Complete resolution was achieved in 8 of 11 eyes after a single AM graft. The epithelial defect persisted after the first AMT in three eyes (27.3%), and a second graft was necessary to achieve complete healing. The corneal epithelial defect healed in an average of 11.0±4.4 days after grafting. After PED resolution, the best-corrected visual acuity significantly improved from 0.66±0.30 logMAR (20/91 Snellen) to 0.58±0.24 logMAR (20/77 Snellen) (P=0.036) compared with baseline. The AM resorbed within 2 weeks in all cases. No complication or recurrence was observed. A sutureless lyophilized AM under the BCL can resolve PEDs with a significant improvement in vision.
Identifiants
pubmed: 36155948
doi: 10.1097/ICL.0000000000000913
pii: 00140068-202210000-00005
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
430-432Informations de copyright
Copyright © 2022 Contact Lens Association of Ophthalmologists.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
Katzman LR, Jeng BH. Management strategies for persistent epithelial defects of the cornea. Saudi J Ophthalmol 2014;28:168–172.
Azuara-Blanco A, Pillai CT, Dua HS. Amniotic membrane transplantation for ocular surface reconstruction. Br J Ophthalmol 1999;83:399–402.
Solomon A, Wajngarten M, Alviano F, et al. Suppression of inflammatory and fibrotic responses in allergic inflammation by the amniotic membrane stromal matrix. Clin Exp Allergy 2005;35:941–948.
Kobayashi N, Kabuyama Y, Sasaki S, et al. Suppression of corneal neovascularization by culture supernatant of human amniotic cells. Cornea 2002;21:62–67.
de Rotth A. Plastic repair of conjunctival defects with fetal membranes. Arch Ophthalmol 1940;23:522–525.
Kheirkhah A, Ghaffari R, Kaghazkanani R, et al. A combined approach of amniotic membrane and oral mucosa transplantation for fornix reconstruction in severe symblepharon. Cornea 2013;32:155–160.
Parmar DP, Bhole PK, Patel PN, et al. Amniotic membrane transplant in acute ocular surface burns in Western India: A tertiary eye care center study. Indian J Ophthalmol 2021;69:58–64.
Yang Y, Fung SSM, Chew H, et al. Amniotic membrane transplantation for Stevens–Johnson syndrome/toxic epidermal necrolysis: The Toronto experience. Br J Ophthalmol 2021;105:1238–1243.
Hanada K, Shimazaki J, Shimmura S, et al. Multilayered amniotic membrane transplantation for severe ulceration of the cornea and sclera. Am J Ophthalmol 2001;131:324–331.
Luccarelli SV, Villani E, Lucentini S, et al. Sutureless “contact lens sandwich” technique for amniotic membrane therapy of central corneal ulcers. Eur J Ophthalmol 2021. Available at: https://journals.sagepub.com/doi/10.1177/11206721211049093?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed# . Accessed October 11, 2021.
doi: https://journals.sagepub.com/doi/10.1177/11206721211049093?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed#
Cheng AMS, Zhao D, Chen R, et al. Accelerated restoration of ocular surface health in dry eye disease by self-retained cryopreserved amniotic membrane. Ocul Surf 2016;14:56–63.
Zhou TE, Robert MC. Comparing ProKera with amniotic membrane transplantation: Indications, outcomes, and costs. Cornea 2021. Available at: https://journals.lww.com/corneajrnl/Abstract/9000/Comparing_ProKera_With_Amniotic_Membrane.95660.aspx . Accessed September 4, 2021.
Shanbhag SS, Hall L, Chodosh J, et al. Long-term outcomes of amniotic membrane treatment in acute Stevens–Johnson syndrome/toxic epidermal necrolysis. Ocul Surf 2020;18:517–522.
Maqsood S, Elsawah K, Dhillon N, et al. Management of persistent corneal epithelial defects with human amniotic membrane-derived dry matrix. Clin Ophthalmol 2021;15:2231–2238.
Hick S, Demers PE, Brunette I, et al. Amniotic membrane transplantation and fibrin glue in the management of corneal ulcers and perforations: A review of 33 cases. Cornea 2005;24:369–377.
Schuerch K, Baeriswyl A, Frueh BE, et al. Efficacy of amniotic membrane transplantation for the treatment of corneal ulcers. Cornea 2020;39:479–483.
Brocks D, Mead OG, Tighe S, et al. Self-retained cryopreserved amniotic membrane for the management of corneal ulcers. Clin Ophthalmol 2020;14:1437–1443.
Suri K, Kosker M, Raber IM, et al. Sutureless amniotic membrane ProKera for ocular surface disorders: Short-term results. Eye Contact Lens 2013;39:341–347.
Mimouni M, Trinh T, Sorkin N, et al. Sutureless dehydrated amniotic membrane for persistent epithelial defects. Eur J Ophthalmol 2021. Available at: https://journals.sagepub.com/doi/10.1177/11206721211011354?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed . Accessed April 22, 2021.
doi: https://journals.sagepub.com/doi/10.1177/11206721211011354?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed